OTCMKTS:CVSI CV Sciences (CVSI) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free CVSI Stock Alerts $0.04 0.00 (0.00%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$0.04▼$0.0450-Day Range$0.03▼$0.0452-Week Range$0.03▼$0.06Volume174,207 shsAverage Volume262,177 shsMarket Capitalization$6.39 millionP/E Ratio3.90Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get CV Sciences alerts: Email Address Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. About CV Sciences Stock (OTCMKTS:CVSI)CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.Read More CVSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVSI Stock News HeadlinesMarch 27, 2024 | wsj.comCV Sciences Inc.March 26, 2024 | finance.yahoo.comCV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet ChewsMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 21, 2024 | prnewswire.comCV SCIENCES, INC. TO ANNOUNCE YEAR END AND FOURTH QUARTER 2023 RESULTS ON MARCH 28, 2024February 22, 2024 | benzinga.comCV Sciences Stock (OTC:CVSI), Short Interest ReportDecember 12, 2023 | finance.yahoo.comCV Sciences, Inc. Acquires Cultured Foods To Enter Plant-Based Food Market, Opening Door For European DistributionNovember 15, 2023 | nz.finance.yahoo.comThe Best Shampoo for Thinning Hair We Tested Is 30% Off Right NowNovember 15, 2023 | finance.yahoo.comCV Sciences, Inc. (PNK:CVSI) Q3 2023 Earnings Call TranscriptMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.November 14, 2023 | benzinga.comHemp-Focused Wellness Company: Revenue Jumps To $4.1M, Gross Margin Peaks At 45.1%November 14, 2023 | msn.comCV Sciences GAAP EPS of $0.00, revenue of $4.09MNovember 14, 2023 | finance.yahoo.comCV Sciences, Inc. Reports Third Quarter 2023 Financial ResultsNovember 12, 2023 | morningstar.comCV Sciences Inc CVSINovember 9, 2023 | finance.yahoo.comCV SCIENCES, INC. TO ANNOUNCE THIRD QUARTER 2023 RESULTS ON NOVEMBER 14, 2023September 5, 2023 | finance.yahoo.comCV Sciences, Inc. Launches Reserve Sleep GummiesAugust 15, 2023 | finance.yahoo.comCV Sciences, Inc. (PNK:CVSI) Q2 2023 Earnings Call TranscriptAugust 14, 2023 | seekingalpha.comCV Sciences GAAP EPS of -$0.01, revenue of $4MAugust 14, 2023 | benzinga.comPublicly Traded Hemp-Focused Wellness Company Reports Q2 Results, Here Is What You Need To KnowAugust 14, 2023 | finance.yahoo.comCV Sciences, Inc. Reports Second Quarter 2023 Financial ResultsAugust 1, 2023 | finance.yahoo.comCV SCIENCES, INC. TO ANNOUNCE SECOND QUARTER 2023 RESULTS ON AUGUST 14, 2023July 8, 2023 | finance.yahoo.comCVSI - CV Sciences, Inc.June 1, 2023 | finance.yahoo.comCV Sciences to Participate in LD Micro Invitational ConferenceMay 15, 2023 | msn.comCV Sciences Inc Q1 Revenue Stagnates YoY, Here Is What You Need To KnowMay 15, 2023 | finance.yahoo.comCV Sciences, Inc. Reports First Quarter 2023 Financial ResultsMay 14, 2023 | markets.businessinsider.comCV Sciences earnings: here's what Wall Street expectsMay 9, 2023 | finance.yahoo.comCV SCIENCES, INC. TO ANNOUNCE FIRST QUARTER 2023 RESULTS ON MAY 15, 2023April 9, 2023 | finance.yahoo.comCV Sciences, Inc. (PNK:CVSI) Q4 2022 Earnings Call TranscriptSee More Headlines Receive CVSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2021Today3/28/2024Next Earnings (Estimated)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CVSI Previous SymbolNASDAQ:CVSI CUSIPN/A CIK1510964 Webwww.cvsciences.com Phone(866) 290-2157Fax619-876-4321Employees42Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E Ratio3.90 Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,210,000.00 Net Margins10.32% Pretax Margin10.03% Return on Equity56.96% Return on Assets15.17% Debt Debt-to-Equity RatioN/A Current Ratio1.39 Quick Ratio0.45 Sales & Book Value Annual Sales$16.20 million Price / Sales0.39 Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-3.90Miscellaneous Outstanding Shares163,760,000Free Float163,561,000Market Cap$6.39 million OptionableNot Optionable Beta0.60 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Joseph D. Dowling (Age 67)CEO, Secretary & Director Comp: $298.98kMr. Joerg Grasser (Age 49)Chief Financial Officer Comp: $210.47kMr. Tim HitchmanVice President of OperationsMr. Jesse KaragianesSenior Vice President of Revenue GrowthMs. Alyssa DunnOperations ManagerKey CompetitorsUniverse PharmaceuticalsNYSE:UPCGraybug VisionNASDAQ:GRAYHoth TherapeuticsNASDAQ:HOTHAvenue TherapeuticsNASDAQ:ATXISonnet BioTherapeuticsNASDAQ:SONNView All Competitors CVSI Stock Analysis - Frequently Asked Questions How have CVSI shares performed in 2024? CV Sciences' stock was trading at $0.0354 on January 1st, 2024. Since then, CVSI shares have increased by 10.2% and is now trading at $0.0390. View the best growth stocks for 2024 here. Are investors shorting CV Sciences? CV Sciences saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 6,800 shares, a drop of 21.8% from the February 29th total of 8,700 shares. Based on an average daily volume of 548,700 shares, the short-interest ratio is currently 0.0 days. View CV Sciences' Short Interest. When is CV Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our CVSI earnings forecast. How were CV Sciences' earnings last quarter? CV Sciences, Inc. (OTCMKTS:CVSI) issued its quarterly earnings data on Thursday, August, 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.03). The business had revenue of $5.13 million for the quarter, compared to analyst estimates of $5.12 million. CV Sciences had a net margin of 10.32% and a trailing twelve-month return on equity of 56.96%. What other stocks do shareholders of CV Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include Cronos Group (CRON), Charlotte's Web (CWBHF), KushCo (KSHB), Organigram (OGI), GW Pharmaceuticals (GWPH), Tilray (TLRY) and Medical Marijuana (MJNA). How do I buy shares of CV Sciences? Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CVSI) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CV Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.